The Group's principal activities are researching, developing and commercializing engineered zinc finger DNA binding proteins for regulation of gene expression and gene modification. The Group has developed a proprietary technology platform enabling the engineering of a class of transcription factors known as Zinc finger DNA-binding proteins (ZFPs). The engineered ZFPs are applicable in pharmaceutical discovery, development of human therapeutics, clinical diagnostics and plant agricultural and biotechnology industry. It operates in the United States.
Alacra Alerts:
Receive alerts on the latest reports on Sangamo Biosciences, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
